REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to tackle tough lymphomas
Disease control Recruiting nowThis early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug HCB301 enters early human trials for tough cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shr…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo aims to tackle tough lymphomas
Disease control Recruiting nowThis phase II trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and ATRA (a vitamin A derivative)—in 24 adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. Participants…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Radioactive antibody combo aims to beat back tough hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial tests a new approach for people with Hodgkin lymphoma that has not responded to treatment or has come back. It combines a radioactive antibody (yttrium-90 labeled anti-CD25) with standard BEAM chemotherapy before a stem cell transplant. The goal is to see if th…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC